# A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects

> **NCT00857493** · PHASE2 · COMPLETED · sponsor: **Bavarian Nordic** · enrollment: 120 (actual)

## Conditions studied

- Smallpox

## Interventions

- **BIOLOGICAL:** IMVAMUNE
- **BIOLOGICAL:** IMVAMUNE

## Key facts

- **NCT ID:** NCT00857493
- **Lead sponsor:** Bavarian Nordic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2019-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00857493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00857493, "A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00857493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*